Loading
A hazard ratio is a number comparing the rate of bad events in two groups. An HR of 0.5 means the risk is halved at any moment.
The hazard ratio (HR) is a single number comparing the rate of bad events, such as death or progression, between two groups in a trial; an HR of one half means the risk is halved at any given moment. It comes from Cox proportional hazards models, an HR below 1 favours the experimental arm, and a confidence interval excluding 1 indicates statistical significance. The HR says nothing about absolute benefit or how long it lasts, so it features in ideas on powering trials for a benefit patients would value, crossover-adjusted survival and Bayesian shrinkage for subgroup claims. The term is referenced by the Pancreatic ductal adenocarcinoma entry, Michael LeBlanc, the bottlenecks on trial design and trial diversity, and ideas on Bayesian borrowing and a rulebook for external control arms.
For patients with advanced melanoma, immunotherapy offers a realistic chance of long-term survival and probably cure, and the ten-year data show that patients who are alive and progression-free at three years rarely die of melanoma afterwards. Nivolumab plus ipilimumab gives the best long-term results but at a high price in serious side effects; nivolumab alone or nivolumab plus relatlimab are alternatives for patients at lower risk or with autoimmune concerns. The trial is also a caution about surrogate endpoints: the survival plateau took years to become visible.
Ribociclib is a second adjuvant CDK4/6 option, and the only one with data in node-negative stage II disease. Roughly 3 in 100 patients avoid a relapse or death at three years, so the decision depends heavily on individual risk, tolerance of a three-year oral drug, and cost. Whether the benefit persists after treatment ends, as it did with abemaciclib, needs longer follow-up.
The evidence behind the stage I de-escalation statement on the triple-negative page: an ordinary haematoxylin and eosin slide identifies a fifth of patients whose outcome without chemotherapy matches treated cohorts. A prospective trial of chemotherapy omission is the missing step.
The best survival ever recorded in a pancreatic cancer trial, and the benchmark every perioperative trial (PREOPANC-3, Alliance A021806) and every adjuvant RAS inhibitor or vaccine trial (RASolute 304, IMCODE003) now has to beat or add to.
The survival result that moved adjuvant olaparib from a disease-free survival approval to an undisputed standard, and the reason germline testing at diagnosis of triple-negative breast cancer is now a treatment decision rather than a family history exercise.
The external validation the 2017 paper asked for; it is why residual cancer burden is reported in UK and European pathology and used as a trial entry criterion rather than an MD Anderson curiosity.
The stage shift the pancreatic cancer page quotes (about three in four surveillance-detected cancers at stage I) and the strongest argument for offering surveillance to every germline carrier found by universal testing, which the NHS does not yet do outside research.
The clearest demonstration that PD-L1 positive in triple-negative breast cancer means different things depending on the kit; with atezolizumab withdrawn, pembrolizumab's 22C3 combined positive score of 10 is the surviving standard, and roughly a quarter of patients get a different answer depending on which assay their laboratory runs.
Shares Clinical benefit response (the gemcitabine trial endpoint), Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients, Absolute versus relative benefit (number needed to treat).
Shares Median survival, Landmark and milestone survival (5-year survival, median follow-up), Absolute versus relative benefit (number needed to treat), Endpoint.
Shares Association of Black race with prostate cancer-specific and other-cause mortality, SWOG 9346: intermittent versus continuous androgen deprivation in metastatic prostate cancer, Intermittent androgen deprivation (IAD), Other-cause mortality.
Shares Data maturity (immature vs mature survival data), Landmark and milestone survival (5-year survival, median follow-up), Statistical significance (P values, alpha, multiplicity), Statistical power, sample size and re-estimation.
Shares Statistical significance (P values, alpha, multiplicity), Statistical power, sample size and re-estimation, Crossover in trials, Kaplan-Meier curve, censoring and proportional hazards.
Shares Association of Black race with prostate cancer-specific and other-cause mortality, Metastasis-free survival (MFS), Number needed to screen (and number needed to diagnose), Other-cause mortality.
Shares Data maturity (immature vs mature survival data), Statistical significance (P values, alpha, multiplicity), Endpoint, Progression-free survival (PFS).
Shares Bayesian shrinkage for subgroup claims to stop false 'works in this group' stories, ASPREE (ASPirin in Reducing Events in the Elderly), VITAL (VITamin D and OmegA-3 TriaL), Deposit trial results as structured data, not just PDFs.